<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">34542988</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK573974</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Institute of Diabetes and Digestive and Kidney Diseases</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</BookTitle><PubDate><Year>2012</Year></PubDate><BeginningDate><Year>2012</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="livertox" part="Viloxazine">Viloxazine</ArticleTitle><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>Viloxazine is a selective norepinephrine reuptake inhibitor that is used in the therapy of attention deficit/hyperactivity disorder in children. Viloxazine has been associated with uncommon and mild serum enzyme elevations during therapy but not with occurrence of clinically apparent liver injury.</AbstractText></Abstract><Sections><Section><SectionTitle book="livertox" part="Viloxazine" sec="Viloxazine.OVERVIEW">OVERVIEW</SectionTitle></Section><Section><SectionTitle book="livertox" part="Viloxazine" sec="Viloxazine.PRODUCT_INFORMATION">PRODUCT INFORMATION</SectionTitle></Section><Section><SectionTitle book="livertox" part="Viloxazine" sec="Viloxazine.CHEMICAL_FORMULA_AND_STRUCTUR">CHEMICAL FORMULA AND STRUCTURE</SectionTitle></Section><Section><SectionTitle book="livertox" part="Viloxazine" sec="Viloxazine.ANNOTATED_BIBLIOGRAPHY">ANNOTATED BIBLIOGRAPHY</SectionTitle></Section></Sections><ContributionDate><Year>2021</Year><Month>8</Month><Day>20</Day></ContributionDate><ReferenceList><Reference><Citation>Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.(Review of hepatotoxicity published in 1999 states that “viloxazine has been mentioned as a cause of jaundice but there are no specific descriptions”).</Citation></Reference><Reference><Citation>FDA . https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf(FDA Drug Approvals website that has product labels [package inserts], letters of approval and full FDA integrated review of the viloxazine application for safety and efficacy which mentions that “no clinically meaningful differences in mean laboratory values were observed in viloxazine treated patients as compared to placebo”, and that transient ALT elevations were uncommon [~6% vs 2% with placebo] modest [only 1% were above twice ULN,] and that no cases of drug-induced liver disease were observed).</Citation></Reference><Reference><Citation>Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13:401–21. [
(Review of the mechanism of action, clinical efficacy and safety of viloxazine used as an antidepressant in adults, mentions that its clinical efficacy in depression is similar to that of the tricyclic antidepressants, although it may have fewer side effects, the most common being nausea, vomiting and headache; no mention of ALT elevations or hepatotoxicity).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">324751</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamura AC, Mauri MC, Girardi T, Panetta B. Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res. 1990;10:293–8. [
(Among 30 adults with alcohol dependence and depression treated with viloxazine [400 mg daily] or placebo for 12 weeks, therapy appeared to alleviate symptoms of depression as well as withdrawal symptoms without changes in biochemical evidence of liver injury [ALT, AST and GGT] in comparison to placebo).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">2079386</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, Nasser A, et al.  A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24:348–58. [
(Among 222 children, ages 6 to 12 years, treated with extended release viloxazine [100, 200, 300 or 400 mg] or placebo once daily for 8 weeks, ADHD rating scores improved in viloxazine- compared to placebo-treated children at all doses, while adverse events were greater and partially dose related with viloxazine including somnolence, fatigue, headache, nausea, irritability, and suicidal ideation [4 vs none] and discontinuations [7% vs none], but there were no serious adverse events and “no clinically significant trends in clinical laboratory tests”).
]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939319</ArticleId><ArticleId IdType="pubmed">30924702</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, et al.  A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–66. [
(Among 460 children, ages 6 to 11 years, with ADHD treated with viloxazine [100 or 200 mg] or placebo daily for 5 weeks, ADHD rating scores improvements and adverse events were more frequent with viloxazine than placebo, and while “no clinical significant trends were found in clinical laboratory results”, transient ALT elevations were recorded in 4% on viloxazine and 3% on placebo).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">32723670</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383:1050–6. [
(Review of the pharmacological therapy of ADHD with discussion of amphetamines, methylphenidate, atomoxetine, guanfacine and clonidine; no mention of ALT elevations during therapy or hepatotoxicity).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">32905677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, et al.  Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684–700. [
(Among 313 children, ages 6 to 11 years, with ADHD treated with viloxazine [200 or 400 mg] or placebo once daily for 8 weeks, improvements in ADHD rating scores were greater with viloxazine than placebo [-17.6 and -17.5 vs -11.7] while common adverse events were somnolence [14% vs 1%], decreased appetite [8% vs 0], fatigue [7% vs 5%], headache [7% vs 1%] and abdominal pain [5% vs 2%], which sometimes led to discontinuation, while laboratory test results were largely mild and transient, one child receiving 400 mg of viloxazine had an elevated ALT value [86 U/L]).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">33750646</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, Chowdhry F, et al.  A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41:370–80. [
(Among 310 adolescents [ages 12 to 17 years] with ADHD treated with viloxazine [200 or 400 mg] or placebo once daily for 6 weeks, improvements in ADHD rating scores were greater with viloxazine vs placebo [-16.0 and -16.5 vs -11.4], and common adverse events include somnolence, headache, poor appetite, nausea, and fatigue, leading to discontinuations in 2.9% vs none, but no one stopped because of laboratory test results; transient ALT elevations arose in 2 viloxazine treated subjects [1%]).
]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8244935</ArticleId><ArticleId IdType="pubmed">34181360</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, et al.  A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51:43–64. [
(Among 297 adolescents [ages 12 to 17 years] with ADHD treated with viloxazine [400 or 600 mg daily] versus placebo for 7 weeks, ADHD rating scores improved more in the viloxazine arms than placebo [-18.3 and -16.7 vs -13.2] while therapy was considered well tolerated at both doses, common adverse events being somnolence, fatigue, headache, nausea and decreased appetite, with 4.5% discontinuation rate, but none for laboratory abnormalities which included ALT elevations in 10.5% and 10.2% on viloxazine vs none on placebo).
]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146561</ArticleId><ArticleId IdType="pubmed">34092822</ArticleId></ArticleIdList></Reference><Reference><Citation>Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, et al.  Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643–53. [
(Review of the history of studies of viloxazine in depression for which it was approved and used in the UK and Europe for over 30 years, with summary of results of previous trials done in adults with depression which reported a favorable safety profile; no mention of ALT elevations or hepatotoxicity).
]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219567</ArticleId><ArticleId IdType="pubmed">34003459</ArticleId></ArticleIdList></Reference><Reference><Citation>Viloxazine ER. (Qelbree) for ADHD. Med Lett Drugs Ther. 2021;63(1627):98–100. [
(Concise review of the mechanism of action, efficacy, safety and costs of viloxazine shortly after its approval for use in the US for ADHD, mentions side effects of somnolence, fatigue, insomnia, anorexia, irritability, nausea, vomiting, headache, weight loss, suicidal ideation and behavior and embryo-fetal toxicity; no mention of ALT elevations or hepatotoxicity).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">34181631</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34542988</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">34542988</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK573974</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Institute of Diabetes and Digestive and Kidney Diseases</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</BookTitle><PubDate><Year>2012</Year></PubDate><BeginningDate><Year>2012</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="livertox" part="Viloxazine">Viloxazine</ArticleTitle><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>Viloxazine is a selective norepinephrine reuptake inhibitor that is used in the therapy of attention deficit/hyperactivity disorder in children. Viloxazine has been associated with uncommon and mild serum enzyme elevations during therapy but not with occurrence of clinically apparent liver injury.</AbstractText></Abstract><Sections><Section><SectionTitle book="livertox" part="Viloxazine" sec="Viloxazine.OVERVIEW">OVERVIEW</SectionTitle></Section><Section><SectionTitle book="livertox" part="Viloxazine" sec="Viloxazine.PRODUCT_INFORMATION">PRODUCT INFORMATION</SectionTitle></Section><Section><SectionTitle book="livertox" part="Viloxazine" sec="Viloxazine.CHEMICAL_FORMULA_AND_STRUCTUR">CHEMICAL FORMULA AND STRUCTURE</SectionTitle></Section><Section><SectionTitle book="livertox" part="Viloxazine" sec="Viloxazine.ANNOTATED_BIBLIOGRAPHY">ANNOTATED BIBLIOGRAPHY</SectionTitle></Section></Sections><ContributionDate><Year>2021</Year><Month>8</Month><Day>20</Day></ContributionDate><ReferenceList><Reference><Citation>Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.(Review of hepatotoxicity published in 1999 states that “viloxazine has been mentioned as a cause of jaundice but there are no specific descriptions”).</Citation></Reference><Reference><Citation>FDA . https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf(FDA Drug Approvals website that has product labels [package inserts], letters of approval and full FDA integrated review of the viloxazine application for safety and efficacy which mentions that “no clinically meaningful differences in mean laboratory values were observed in viloxazine treated patients as compared to placebo”, and that transient ALT elevations were uncommon [~6% vs 2% with placebo] modest [only 1% were above twice ULN,] and that no cases of drug-induced liver disease were observed).</Citation></Reference><Reference><Citation>Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13:401–21. [
(Review of the mechanism of action, clinical efficacy and safety of viloxazine used as an antidepressant in adults, mentions that its clinical efficacy in depression is similar to that of the tricyclic antidepressants, although it may have fewer side effects, the most common being nausea, vomiting and headache; no mention of ALT elevations or hepatotoxicity).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">324751</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamura AC, Mauri MC, Girardi T, Panetta B. Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res. 1990;10:293–8. [
(Among 30 adults with alcohol dependence and depression treated with viloxazine [400 mg daily] or placebo for 12 weeks, therapy appeared to alleviate symptoms of depression as well as withdrawal symptoms without changes in biochemical evidence of liver injury [ALT, AST and GGT] in comparison to placebo).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">2079386</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, Nasser A, et al.  A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24:348–58. [
(Among 222 children, ages 6 to 12 years, treated with extended release viloxazine [100, 200, 300 or 400 mg] or placebo once daily for 8 weeks, ADHD rating scores improved in viloxazine- compared to placebo-treated children at all doses, while adverse events were greater and partially dose related with viloxazine including somnolence, fatigue, headache, nausea, irritability, and suicidal ideation [4 vs none] and discontinuations [7% vs none], but there were no serious adverse events and “no clinically significant trends in clinical laboratory tests”).
]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939319</ArticleId><ArticleId IdType="pubmed">30924702</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, et al.  A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–66. [
(Among 460 children, ages 6 to 11 years, with ADHD treated with viloxazine [100 or 200 mg] or placebo daily for 5 weeks, ADHD rating scores improvements and adverse events were more frequent with viloxazine than placebo, and while “no clinical significant trends were found in clinical laboratory results”, transient ALT elevations were recorded in 4% on viloxazine and 3% on placebo).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">32723670</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383:1050–6. [
(Review of the pharmacological therapy of ADHD with discussion of amphetamines, methylphenidate, atomoxetine, guanfacine and clonidine; no mention of ALT elevations during therapy or hepatotoxicity).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">32905677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, et al.  Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684–700. [
(Among 313 children, ages 6 to 11 years, with ADHD treated with viloxazine [200 or 400 mg] or placebo once daily for 8 weeks, improvements in ADHD rating scores were greater with viloxazine than placebo [-17.6 and -17.5 vs -11.7] while common adverse events were somnolence [14% vs 1%], decreased appetite [8% vs 0], fatigue [7% vs 5%], headache [7% vs 1%] and abdominal pain [5% vs 2%], which sometimes led to discontinuation, while laboratory test results were largely mild and transient, one child receiving 400 mg of viloxazine had an elevated ALT value [86 U/L]).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">33750646</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, Chowdhry F, et al.  A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41:370–80. [
(Among 310 adolescents [ages 12 to 17 years] with ADHD treated with viloxazine [200 or 400 mg] or placebo once daily for 6 weeks, improvements in ADHD rating scores were greater with viloxazine vs placebo [-16.0 and -16.5 vs -11.4], and common adverse events include somnolence, headache, poor appetite, nausea, and fatigue, leading to discontinuations in 2.9% vs none, but no one stopped because of laboratory test results; transient ALT elevations arose in 2 viloxazine treated subjects [1%]).
]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8244935</ArticleId><ArticleId IdType="pubmed">34181360</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, et al.  A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51:43–64. [
(Among 297 adolescents [ages 12 to 17 years] with ADHD treated with viloxazine [400 or 600 mg daily] versus placebo for 7 weeks, ADHD rating scores improved more in the viloxazine arms than placebo [-18.3 and -16.7 vs -13.2] while therapy was considered well tolerated at both doses, common adverse events being somnolence, fatigue, headache, nausea and decreased appetite, with 4.5% discontinuation rate, but none for laboratory abnormalities which included ALT elevations in 10.5% and 10.2% on viloxazine vs none on placebo).
]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146561</ArticleId><ArticleId IdType="pubmed">34092822</ArticleId></ArticleIdList></Reference><Reference><Citation>Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, et al.  Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643–53. [
(Review of the history of studies of viloxazine in depression for which it was approved and used in the UK and Europe for over 30 years, with summary of results of previous trials done in adults with depression which reported a favorable safety profile; no mention of ALT elevations or hepatotoxicity).
]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219567</ArticleId><ArticleId IdType="pubmed">34003459</ArticleId></ArticleIdList></Reference><Reference><Citation>Viloxazine ER. (Qelbree) for ADHD. Med Lett Drugs Ther. 2021;63(1627):98–100. [
(Concise review of the mechanism of action, efficacy, safety and costs of viloxazine shortly after its approval for use in the US for ADHD, mentions side effects of somnolence, fatigue, insomnia, anorexia, irritability, nausea, vomiting, headache, weight loss, suicidal ideation and behavior and embryo-fetal toxicity; no mention of ALT elevations or hepatotoxicity).
]</Citation><ArticleIdList><ArticleId IdType="pubmed">34181631</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34542988</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
